Adcock DM, Gosselin R. Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review. Thromb Res. 2015; 136(1): 7-12. PubMed
Anderson JA, Weitz JI. Hypercoagulable states. Clin Chest Med. 2010; 31(4): 659-73. PubMed
Dale BJ, Ginsberg JS, Johnston M, Hirsh J, Weitz JI, Eikelboom JW. Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents. J Thromb Haemost. 2014; 12(11): 1810-5. PubMed
Favaloro EJ, McDonald D, Lippi G. Laboratory investigation of thrombophilia: the good, the bad, and the ugly. Semin Thromb Hemost. 2009; 35(7): 695-710. PubMed
Favaloro EJ. The futility of thrombophilia testing. Clin Chem Lab Med. 2014; 52(4): 499-503. PubMed
Franchini M. The utility of thrombophilia testing. Clin Chem Lab Med. 2014; 52(4): 495-7. PubMed
Hillarp A, Baghaei F, Blixter F, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Lindahl TL. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost. 2011; 9(1): 133-9. PubMed
Hossain N, Paidas MJ. Inherited thrombophilia: diagnosis and anticoagulation treatment in pregnancy. Clin Lab Med. 2013; 33(2): 377-90. PubMed
Johnson NV, Khor B, Van Cott EM. Advances in laboratory testing for thrombophilia. Am J Hematol. 2012; 87 Suppl 1: S108-12. PubMed
Lindhoff-Last E, Luxembourg B. Evidence-based indications for thrombophilia screening. Vasa. 2008; 37(1): 19-30. PubMed
Linkins LA, Julian JA, Rischke J, Hirsh J, Weitz JI. In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. Thromb Res. 2002; 107(5): 241-4. PubMed
Lippi G. Thrombophilia testing. Useful or hype? Clin Chem Lab Med. 2014; 52(4): 467-9. PubMed
Middeldorp S. Evidence-based approach to thrombophilia testing. J Thromb Thrombolysis. 2011; 31(3): 275-81. PubMed
Molinaro RJ, Szlam F, Levy JH, Fantz CR, Tanaka KA. Low plasma fibrinogen levels with the Clauss method during anticoagulation with bivalirudin. Anesthesiology. 2008; 109(1): 160-1. PubMed
Samama MM, Martinoli J, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost. 2010; 103(4): 815-25. PubMed
Trampus-Bakija A. Pediatric thrombosis. Clin Chem Lab Med. 2010; 48 Suppl 1: S97-S104. PubMed
Tsutsumi Y, Shimono J, Ohhigashi H, Ito S, Shiratori S, Teshima T. Analysis of the influence of dabigatran on coagulation factors and inhibitors. Int J Lab Hematol. 2015; 37(2): 225-30. PubMed
van Ommen H, Middeldorp S. Thrombophilia in childhood: to test or not to test. Semin Thromb Hemost. 2011; 37(7): 794-801. PubMed
Walker P, Gregg AR. Screening, testing, or personalized medicine: where do inherited thrombophilias fit best? Obstet Gynecol Clin North Am. 2010; 37(1): 87-107, Table of Contents. PubMed
Whitlatch NL, Ortel TL. Thrombophilias: when should we test and how does it help? Semin Respir Crit Care Med. 2008; 29(1): 25-39. PubMed
Yang JY, Chan AK. Pediatric thrombophilia. Pediatr Clin North Am. 2013; 60(6): 1443-62. PubMed